Advanced search
Publication Cover
HIV Clinical Trials Volume 4, 2003 - Issue 2
Submit an article Journal homepage
20
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

The Concept of Structured Treatment Interruptions in the Management of Patients with Human Immunodeficiency Virus (HIV) Disease: Where Are We Currently?

Vincent IdemyorAdvocate Bethany Hospital and Department of MedicineUniversity of Illinois College of Medicine, Chicago, IllinoisUSACorrespondence[email protected]
Pages 79-83 | Published online: 14 Jan 2015

REFERENCES

  • Idemyor V. Continuing debate over HIV therapy initiation. HIV Clin Trials. 2002;3(2):173–176.
  • Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents. February 4, 2002. Available at: http://hivatis.org. Accessed June 17, 2002.
  • Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral therapy for HIV infection in adults: updated recommenda-tions of the International AIDS Society - USA panel. JAMA. 2002;288:222–235.
  • Benson CA. Key updates from recent research confer-ences: structured treatment interruption, intermittent treat-ment strategies, and new drugs in development. Topics HIV Med. 2001 ;9(6):4–9.
  • Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy [letter]. N Engl J Med. 1999;340:1683–1684.
  • Ortiz GM, Nixon DF, Trykola A, et al. HIV-1 specific immune responses in subjects who temporarily contain virus repli-cation after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999;104:R13–R18.
  • Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with con-trol of viremia. Science. 1997;278:1447–1450.
  • Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523–526.
  • Hoen B, Burgard M, Fournier I, et al. Structured treatment interruptions (STI) in acute seroconverters: interim results of the multicenter prospective PRIMSTOP pilot trial (ANRS 100). In: Program and abstracts of the Ninth Conference on Retroviruses and Oppportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 530–M.
  • Hirschel B, Fagard C, Oxenius A, Gunthard H, Garcia Fl. SSITT: a prospective trial of treatment interruptions in HIV infection. In: Program and abstracts of the Ninth Confer-ence on Retroviruses and Opportunistic Infections; Febru-ary 24–28, 2002; Seattle, Washington. Abstract 528–M.
  • Carcelain G, Tubiana R, Samri A, et al. Transient mobiliza-tion of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during inter-mittent antiretroviral therapy in chronic HIV type-1 infec-tion. J ViroL 200175: 234–241.
  • Ruiz L, Carcelain G, Martinez-Picado J, et al. HIV dynamics and T-cell immunity after structured treatment interrup-tions in chronic HIV-1 infection. AIDS. 2001;15:F19–F27.
  • Lori F, Foli A, Maserati R, et al. Control of HIV during a structured treatment interruption in chronically infected in-dividuals with vigorous T cell responses. HIV Clin Trials. 2002;3(2):115–124.
  • Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Se-lection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS. 2002;16:895–899.
  • Miller V, Sabin C, Hertogs K, et al. Virological and immuno-logical effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857–2867.
  • Deeks SG, Wrin T, Liegler T, et al. Virologic and immuno-logic consequences of discontinuing combination antiretroviral therapy in HIV-infected patients with detect-able viremia. N Engl J Med. 2001344: 472–480.
  • Lundgren JD, Vella S, Paddam L, et al. Interruption/stop-ping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA study. In: Program and ab-stracts of the Ninth Conference on Retroviruses and Op-portunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 48.
  • Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immuno-logic, and toxicity parameters. Proc Nat/ Acad Sci USA. 200198: 15161–15166.
  • Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
  • Available at: http://www.smart-trial.org/download/CPCRAPressRelease.pdf. Accessed January 27, 2002.
  • Available at: http://www.staccatotrial.ch. Accessed August 30, 2002.
  • Katlama C, Dominguez S, Duvivier C, et al. Benefits of treatment interruption (TI) in patients with multiple therapy failures, CD4 cells <200/mm3 and hiv rna >50,000 cp/mL (GIGHAART ANRS 097). In: Program and abstracts of the XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract WePeB5887.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.